Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
daNIS-3 second-line metastatic colorectal cancer platform study
2021-000553-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nisevokitug, tislelizumab, bevacizumab, fluorouracil, oxaliplatin and 2 more in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) (2 arms), sponsored by Novartis. Primary endpoint: Incidence of dose-limiting toxicities. Started Aug 2021; status: completed.
02
Drugs
nisevokitugtislelizumabbevacizumabfluorouraciloxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2021-000553-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000553-40.